Patents by Inventor Jasper Dingemanse

Jasper Dingemanse has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Crystalline form of the compound (s)-3-{4-[5-(2-cyclopentyl-6-methoxy-pyridin-4-yl)-[1,2,4]oxadiazol-3-yl]-2-ethyl-6-methyl-phenoxy}-propane-1,2-diol
    Patent number: 11834443
    Abstract: The present invention relates to a crystalline form of the compound (S)-3-{4-[5-(2-cyclopentyl-6-methoxy-pyridin-4-yl)-[1,2,4]oxadiazol-3-yl]-2-ethyl-6-methyl-phenoxy}-propane-1,2-diol.
    Type: Grant
    Filed: July 1, 2022
    Date of Patent: December 5, 2023
    Assignee: Idorsia Pharmaceuticals Ltd
    Inventors: Cyrille Lescop, Jasper Dingemanse, Andreas Krause
  • Dosing regimen for a selective S1Preceptor agonist
    Patent number: 11771683
    Abstract: The present invention relates to a dosing regimen for (R)-5-[3-chloro-4-(2,3-dihydroxy-propoxy)-benz[Z]ylidene]-2-([Z]-propylimino)-3-o-tolyl-thiazolidin-4-one.
    Type: Grant
    Filed: November 5, 2020
    Date of Patent: October 3, 2023
    Assignee: Actelion Pharmaceuticals Ltd
    Inventors: Jasper Dingemanse, Matthias Hoch, Andreas Krause
  • DOSING REGIMEN FOR A SELECTIVE S1P1 RECEPTOR AGONIST
    Publication number: 20230131600
    Abstract: The present invention relates to a dosing regimen for (R)-5-[3-chloro-4-(2,3-dihydroxy-propoxy)-benz[Z]ylidene]-2-([Z]-propylimmo)-3-o-tolyl-thiazolidin-4-one.
    Type: Application
    Filed: October 13, 2022
    Publication date: April 27, 2023
    Applicant: ACTELION PHARMACEUTICALS LTD
    Inventors: Jasper DINGEMANSE, Matthias HOCH, Andreas KRAUSE
  • CRYSTALLINE FORM OF THE COMPOUND (S)-3-{4-[5-(2-CYCLOPENTYL-6-METHOXY-PYRIDIN-4-YL)-[1,2,4]OXADIAZOL-3-YL]-2-ETHYL-6-METHYL-PHENOXY}-PROPANE-1,2-DIOL
    Publication number: 20230002365
    Abstract: The present invention relates to a crystalline form of the compound (S)-3-{4-[5-(2-cyclopentyl-6-methoxy-pyridin-4-yl)-[1,2,4]oxadiazol-3-yl]-2-ethyl-6-methyl-phenoxy}-propane-1,2-diol.
    Type: Application
    Filed: July 1, 2022
    Publication date: January 5, 2023
    Inventors: Cyrille LESCOP, Jasper DINGEMANSE, Andreas KRAUSE
  • Crystalline form of the compound (S)-3-{4-[5-(2-cyclopentyl-6-methoxy-pyridin-4-yl)-[1,2,4]oxadiazol-3-yl]-2-ethyl-6-methyl-phenox
    Patent number: 11390615
    Abstract: The present invention relates to a crystalline form of the compound (S)-3-{4-[5-(2-cyclopentyl-6-methoxy-pyridin-4-yl)-[1,2,4]oxadiazol-3-yl]-2-ethyl-6-methyl-phenoxy}-propane-1,2-diol.
    Type: Grant
    Filed: October 14, 2020
    Date of Patent: July 19, 2022
    Assignee: IDORSIA PHARMACEUTICALS LTD
    Inventors: Cyrille Lescop, Jasper Dingemanse, Andreas Krause
  • DOSING REGIMEN FOR A SELECTIVE S1P1 RECEPTOR AGONIST
    Publication number: 20210401811
    Abstract: The present invention relates to a dosing regimen for a selective S1P1 receptor agonist, whereby the selective S1P1 receptor agonist is administered to a subject in such a way that during the initial treatment phase the selective S1P1 receptor agonist is administered at a dose which induces desensitization of the heart wherein said dose is below the target dose, and at a dosing frequency that sustains desensitization of the heart, until no further acute heart rate reduction occurs, followed by dose up-titration to the target dose of the selective S1P1 receptor agonist.
    Type: Application
    Filed: September 9, 2021
    Publication date: December 30, 2021
    Applicant: ACTELION PHARMACEUTICALS LTD
    Inventors: Patrick BROSSARD, Jasper DINGEMANSE, Oliver NAYLER, Michael SCHERZ, Beat STEINER
  • DOSING REGIMEN FOR A SELECTIVE S1P1 RECEPTOR AGONIST
    Publication number: 20210052555
    Abstract: The present invention relates to a dosing regimen for (R)-5-[3-chloro-4-(2,3-dihydroxy-propoxy)-benz[Z]ylidene]-2-([Z]-propylimino)-3-o-tolyl-thiazolidin-4-one.
    Type: Application
    Filed: November 5, 2020
    Publication date: February 25, 2021
    Applicant: ACTELION PHARMACEUTICALS LTD
    Inventors: Jasper DINGEMANSE, Matthias HOCH, Andreas KRAUSE
  • CRYSTALLINE FORM OF THE COMPOUND (S)-3-{4-[5-(2-CYCLOPENTYL-6-METHOXY-PYRIDIN-4-YL)-[1,2,4]OXADIAZOL-3-YL]-2-ETHYL-6-METHYL-PHENOXY}-PROPANE-1,2-DIOL
    Publication number: 20210024513
    Abstract: The present invention relates to a crystalline form of the compound (S)-3-{4-[5-(2-cyclopentyl-6-methoxy-pyridin-4-yl)-[1,2,4]oxadiazol-3-yl]-2-ethyl-6-methyl-phenoxy}-propane-1,2-diol.
    Type: Application
    Filed: October 14, 2020
    Publication date: January 28, 2021
    Applicant: IDORSIA PHARMACEUTICALS LTD
    Inventors: Cyrille LESCOP, Jasper DINGEMANSE, Andreas KRAUSE
  • Dosing regimen for a selective S1Preceptor agonist
    Patent number: 10857134
    Abstract: The present invention relates to a dosing regimen for (R)-5-[3-chloro-4-(2,3-dihydroxy-propoxy)-benz[Z]ylidene]-2-([Z]-propylimino)-3-o-tolyl-thiazolidin-4-one.
    Type: Grant
    Filed: January 29, 2019
    Date of Patent: December 8, 2020
    Assignee: ACTELION PHARMACEUTICALS LTD
    Inventors: Jasper Dingemanse, Matthias Hoch, Andreas Krause
  • Crystalline form of the compound (S)-3-{4-[5-(2-cyclopentyl-6-methoxy-pyridin-4-yl)-[1,2,4]oxadiazol-3-yl]-2-ethyl-6-methyl-phenoxy}-propane-1,2-diol
    Patent number: 10836754
    Abstract: The present invention relates to a crystalline form of the compound (S)-3-{4-[5-(2-cyclopentyl-6-methoxy-pyridin-4-yl)-[1,2,4]oxadiazol-3-yl]-2-ethyl-6-methyl-phenoxy}-propane-1,2-diol.
    Type: Grant
    Filed: July 3, 2019
    Date of Patent: November 17, 2020
    Assignee: IDORSIA PHARMACEUTICALS LTD
    Inventors: Cyrille Lescop, Jasper Dingemanse, Andreas Krause
  • Dosing regimen for a selective S1Pagonist
    Patent number: 10660880
    Abstract: The present invention relates to a dosing regimen for a selective S1P1 receptor agonist, whereby the selective S1P1 receptor agonist is administered to a subject in such a way that during the initial treatment phase the selective S1P1 receptor agonist is administered at a dose which induces desensitization of the heart wherein said dose is below the target dose, and at a dosing frequency that sustains desensitization of the heart, until no further acute heart rate reduction occurs, followed by dose up-titration to the target dose of the selective S1P1 receptor agonist.
    Type: Grant
    Filed: July 2, 2014
    Date of Patent: May 26, 2020
    Assignee: ACTELION PHARMACEUTICALS LTD
    Inventors: Patrick Brossard, Jasper Dingemanse, Oliver Nayler, Michael Scherz, Beat Steiner
  • DOSING REGIMEN FOR A SELECTIVE S1P1 RECEPTOR AGONIST
    Publication number: 20190151292
    Abstract: The present invention relates to a dosing regimen for (R)-5-[3-chloro-4-(2,3-dihydroxy-propoxy)-benz[Z]ylidene]-2-([Z]-propylimino)-3-o-tolyl-thiazolidin-4-one.
    Type: Application
    Filed: January 29, 2019
    Publication date: May 23, 2019
    Applicant: ACTELION PHARMACEUTICALS LTD
    Inventors: Jasper DINGEMANSE, Matthias HOCH, Andres KRAUSE
  • Dosing regimen for a selective S1Preceptor agonist
    Patent number: 10251867
    Abstract: The present invention relates to a dosing regimen for a selective S1P1 receptor agonist, whereby the selective S1P1 receptor agonist is administered to a subject in such a way that during the initial treatment phase the selective S1P1 receptor agonist is administered at a dose which induces desensitization of the heart wherein said dose is below the target dose, and at a dosing frequency that sustains desensitization of the heart, until no further acute heart rate reduction occurs, followed by dose up-titration to the target dose of the selective S1P1 receptor agonist.
    Type: Grant
    Filed: June 5, 2015
    Date of Patent: April 9, 2019
    Assignee: ACTELION PHARMACEUTICALS LTD.
    Inventors: Patrick Brossard, Jasper Dingemanse, Oliver Nayler, Michael Scherz, Beat Steiner
  • Dosing regimen for a selective S1Preceptor agonist
    Patent number: 10220023
    Abstract: The present invention relates to a dosing regimen for (R)-5-[3-chloro-4-(2,3-dihydroxy-propoxy)-benz[Z]ylidene]-2-([Z]-propylimino)-3-o-tolyl-thiazolidin-4-one.
    Type: Grant
    Filed: December 10, 2015
    Date of Patent: March 5, 2019
    Assignee: ACTELION PHARMACEUTICALS LTD
    Inventors: Jasper Dingemanse, Matthias Hoch, Andreas Krause
  • DOSING REGIMEN FOR A SELECTIVE S1P1 RECEPTOR AGONIST
    Publication number: 20180147188
    Abstract: The present invention relates to a dosing regimen for (R)-5-[3-chloro-4-(2,3-dihydroxy-propoxy)-benz[Z]ylidene]-2-([Z]-propylimino)-3-o-tolyl-thiazolidin-4-one.
    Type: Application
    Filed: December 10, 2015
    Publication date: May 31, 2018
    Applicant: ACTELION PHARMACEUTICALS LTD
    Inventors: Jasper DINGEMANSE, Matthias HOCH, Andreas KRAUSE
  • DOSING REGIMEN FOR A SELECTIVE S1P1 RECEPTOR AGONIST
    Publication number: 20170319555
    Abstract: The present invention relates to a dosing regimen for (R)-5-[3-chloro-4-(2,3-dihydroxy-propoxy)-benz[Z]ylidene]-2-([Z]-propylimino)-3-o-tolyl-thiazolidin-4-one.
    Type: Application
    Filed: December 10, 2015
    Publication date: November 9, 2017
    Applicant: ACTELION PHARMACEUTICALS LTD
    Inventors: Jasper DINGEMANSE, Matthias HOCH, Andreas KRAUSE
  • DOSING REGIMEN FOR A SELECTIVE S1P1 RECEPTOR AGONIST
    Publication number: 20150265580
    Abstract: The present invention relates to a dosing regimen for a selective S1P1 receptor agonist, whereby the selective S1P1 receptor agonist is administered to a subject in such a way that during the initial treatment phase the selective S1P1 receptor agonist is administered at a dose which induces desensitization of the heart wherein said dose is below the target dose, and at a dosing frequency that sustains desensitization of the heart, until no further acute heart rate reduction occurs, followed by dose up-titration to the target dose of the selective S1P1 receptor agonist.
    Type: Application
    Filed: June 5, 2015
    Publication date: September 24, 2015
    Inventors: PATRICK BROSSARD, JASPER DINGEMANSE, OLIVER NAYLER, MICHAEL SCHERZ, BEAT STEINER
  • DOSING REGIMEN FOR A SELECTIVE S1P1 RECEPTOR AGONIST
    Publication number: 20140315964
    Abstract: The present invention relates to a dosing regimen for a selective S1P1 receptor agonist, whereby the selective S1P1 receptor agonist is administered to a subject in such a way that during the initial treatment phase the selective S1P1 receptor agonist is administered at a dose which induces desensitization of the heart wherein said dose is below the target dose, and at a dosing frequency that sustains desensitization of the heart, until no further acute heart rate reduction occurs, followed by dose up-titration to the target dose of the selective S1P1 receptor agonist.
    Type: Application
    Filed: July 2, 2014
    Publication date: October 23, 2014
    Inventors: PATRICK BROSSARD, Jasper Dingemanse, Oliver Nayler, Michael Scherz, Beat Steiner
  • DOSING REGIMEN FOR A SELECTIVE S1P1 AGONIST
    Publication number: 20140316140
    Abstract: The present invention relates to a dosing regimen for a selective S1P1 receptor agonist, whereby the selective S1P1 receptor agonist is administered to a subject in such a way that during the initial treatment phase the selective S1P1 receptor agonist is administered at a dose which induces desensitization of the heart wherein said dose is below the target dose, and at a dosing frequency that sustains desensitization of the heart, until no further acute heart rate reduction occurs, followed by dose up-titration to the target dose of the selective S1P1 receptor agonist.
    Type: Application
    Filed: July 2, 2014
    Publication date: October 23, 2014
    Inventors: PATRICK BROSSARD, Jasper DINGEMANSE, Oliver NAYLER, Michael SCHERZ, Beat STEINER
  • DOSING REGIMEN FOR A SELECTIVE S1P1 RECEPTOR AGONIST
    Publication number: 20140303217
    Abstract: The present invention relates to a dosing regimen for a selective S1P1 receptor agonist, whereby the selective S1P1 receptor agonist is administered to a subject in such a way that during the initial treatment phase the selective S1P1 receptor agonist is administered at a dose which induces desensitization of the heart wherein said dose is below the target dose, and at a dosing frequency that sustains desensitization of the heart, until no further acute heart rate reduction occurs, followed by dose up-titration to the target dose of the selective S1P1 receptor agonist.
    Type: Application
    Filed: June 18, 2014
    Publication date: October 9, 2014
    Inventors: Patrick BROSSARD, Jasper DINGEMANSE, Oliver NAYLER, Michael SCHERZ, Beat STEINER